• Polyrizon received central IRB clearance from BRANY to launch its first human trial of NASARIX nasal spray for seasonal allergic rhinitis.
• The study will compare NASARIX with a saline spray control, clearing the path toward site activation and patient enrollment.
• The IRB approval was granted June 18, 2026, remaining in effect through June 17, 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290844PRIMZONEFULLFEED9754015) on June 29, 2026, and is solely responsible for the information contained therein.